Search
Vaccines Treatment Options in Canada
A collection of 103 research studies where Vaccines is the interventional treatment. These studies are located in the Canada . Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
85 - 96 of 103
Immune Responses in Patients Treated With Raltegravir
Withdrawn
Hypothesis: Treatment with raltegravir does not alter V(D)J recombination or immune responses to neoantigens.
A process known as V(D)J recombination is essential for developing lymphocytes and the specific functioning of the immune system. Raltegravir is the first approved drug of the new integrase inhibitor class of anti-HIV drugs. Integrase inhibitors have been shown in some studies to interfere with DNA cleavage and the activities of RAG-1/2. These studies suggest a potential to affect aspec... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/13/2015
Locations: Immune Deficiency Treatment Centre, Montreal General Hospital, McGill University Health Centre, Montreal, Quebec
Conditions: HIV Infections
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
Completed
Primary objective is to determine if antibody responses to HPV types 16 \& 18 are non-inferior after a 2-dose paediatric regimen as compared to a 3-dose adult regimen of Q-HPV vaccination, with responses measured at Month 7.
Gender:
FEMALE
Ages:
Between 9 years and 26 years
Trial Updated:
04/08/2015
Locations: Vaccine Evaluation Centre, Vancouver, British Columbia
Conditions: Cervical Cancer, Genital Warts
A Study of FluzoneĀ® High-Dose Vaccine Compared With FluzoneĀ® Vaccine In Elderly Adults
Completed
The aim of this study is to determine the efficacy of Fluzone High-Dose compared to standard dose Fluzone for laboratory-confirmed or culture-confirmed influenza caused by influenza types/subtypes that are similar (for laboratory-confirmed) or antigenically similar (for culture-confirmed) to those contained in the respective annual vaccine formulations.
Primary Objective:
* To compare the clinical efficacy of Fluzone High-Dose to that of Fluzone in elderly adults, with respect to laboratory-co... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/30/2015
Locations: Not set, Mobile, Alabama +112 locations
Conditions: Influenza
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Completed
Primary objective:
* To determine the safety and immunogenicity of tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) compared to tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) and Hepatitis B vaccine administered concurrently in adolescents 11-14 years of age.
Secondary objective:
* To determine whether con... Read More
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
03/24/2015
Locations: Not set, Winnipeg, Manitoba
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Completed
The purpose of this study is to evaluate the safety, immunogenicity and induction of immune memory after two or three doses of Novartis (Formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy infants.
Gender:
ALL
Ages:
Between 2 months and 6 months
Trial Updated:
06/16/2014
Locations: Vaccine Evaluation Center, Vancouver, British Columbia +2 locations
Conditions: Prevention of Meningococcal Disease
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
Completed
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
04/03/2014
Locations: 37 Alabama Clinical Therapeutics LLC 52 Medical Park East Drive Suite 203, Birmingham, Alabama +45 locations
Conditions: Meningococcal Disease
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
Completed
The purpose of this study is to determine the role of HIV-specific CD4 T cell responses and immune responses dependent upon these CD4 responses that develop when antiretroviral drugs are started during acute or recent HIV infection, whether these CD4 responses can be enhanced with a therapeutic HIV vaccine (HIV-1 immunogen), and what pattern of HIV-specific immune responses is associated with control of HIV upon discontinuation of antiretroviral drugs during an analytical therapeutic interruptio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/19/2013
Locations: New York University School of Medicine, New York, New York +1 locations
Conditions: HIV Infections
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama +236 locations
Conditions: Lung Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells.
PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: University of Alabama Comprehensive Cancer Center, Birmingham, Alabama +59 locations
Conditions: Ovarian Cancer
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: MBCCOP - Gulf Coast, Mobile, Alabama +99 locations
Conditions: Lung Cancer
Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)
Completed
This study will evaluate the effect of treatment with fingolimod on the immune response following seasonal influenza vaccination and tetanus booster injection in patients with relapsing MS.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
05/15/2012
Locations: Novartis Investigative Site, Aalst, Not set +24 locations
Conditions: Relapsing Multiple Sclerosis
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Completed
The purpose of this study is to determine the safety and efficacy of MDX-010 (ipilimumab, BMS-734016) (anti-CTLA4) in combination with MDX-1379 (gp100, BMS-734019) in patients with previously treated, unresectable Stage III or IV melanoma. Survival time will be evaluated, as well as patient responses and time to disease progression. Eligible patients are those who in response to a single regimen containing interleukin-2 (IL-2), dacarbazine, and/or temozolomide, have 1) relapsed following an obje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2011
Locations: Arizona Cancer Center, Tucson, Arizona +208 locations
Conditions: Melanoma, Metastases
85 - 96 of 103